DC/MM Fusion Vaccine + BCMA CAR-T for Multiple Myeloma

This trial explores a new treatment for people with multiple myeloma, a type of blood cancer that has returned or doesn’t respond to standard treatment. It combines a personalized cancer vaccine (DC/MM fusion vaccine) with a special cell therapy (BCMA CAR-T cell therapy) to assess safety and effectiveness. People who have received standard CAR-T therapy for multiple myeloma but need more options might be suitable candidates. Participants will receive the vaccine and therapy, followed by regular monitoring to track their progress. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this innovative therapy.

The trial information does not specify if you need to stop taking your current medications. However, you cannot be on other investigational drugs or receive myeloma-directed therapy after CAR T-cell treatment.

Research has shown that the DC/MM fusion vaccine is generally well-tolerated, meaning it is safe for most people and doesn't cause serious side effects. Studies have found that this vaccine can help the immune system fight tumors and stabilize the disease in many patients.

BCMA CAR-T cell therapy is already a common treatment for multiple myeloma, having been tested for safety and effectiveness in other studies. While any treatment can have side effects, its status as a standard treatment indicates it is considered safe for this condition.

The DC/MM Fusion Vaccine is unique because it combines dendritic cells with tumor cells to create a personalized cancer vaccine, potentially enhancing the immune system's ability to recognize and destroy multiple myeloma cells. Most treatments for multiple myeloma, like BCMA CAR-T cell therapy, focus on modifying T-cells to target cancer. However, this vaccine approach aims to boost the body's natural immune response in a more targeted way. Researchers are excited about this treatment because it represents a novel strategy that could improve patient outcomes by leveraging the body's own defense mechanisms in a highly specific manner.

Studies have shown that the DC/MM fusion vaccine holds promise for treating multiple myeloma. This personalized cancer vaccine uses the patient’s own cells to help the immune system attack cancer. Research indicates that the vaccine often stabilizes the disease and triggers the body to fight the tumor. In one study, 52.9% of patients had a complete response (CR) after one year, indicating effectiveness. In this trial, participants will receive the DC/MM fusion vaccine alongside standard-of-care BCMA CAR-T cell therapy. Initial findings suggest that combining this vaccine with other treatments, like BCMA CAR-T cell therapy, could enhance its effectiveness.¹³⁶⁷⁸